ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2010
On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience.
Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema.Allergy · 2026Guideline
- Expert consensus on the long-term use of lanadelumab in hereditary angioedema: Toward harmonized care.Allergologie select · 2026Article
- The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.The World Allergy Organization journal · 2022Article
- Therapeutic management of hereditary angioedema: past, present, and future.Balkan medical journal · 2021Article
- Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.Nursing open · 2019Article
- Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019Observational
- Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.Paediatric drugs · 2018Review
- Article
- Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International BerinertDrugs & aging · 2016Observational
- The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema.Clinical reviews in allergy & immunology · 2016Review
- High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.Orphanet journal of rare diseases · 2016Article
- Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.Patient preference and adherence · 2016Review
- Paediatric hereditary angioedema: a survey of UK service provision and patient experience.Clinical and experimental immunology · 2014Article
- Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe.Orphanet journal of rare diseases · 2014Article
- Hereditary angioedema: epidemiology, management, and role of icatibant.Biologics : targets & therapy · 2013Article
- WAO Guideline for the Management of Hereditary Angioedema.The World Allergy Organization journal · 2012Article
- An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.Core evidence · 2012Article
- Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2011Article
- Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies.The World Allergy Organization journal · 2011Article
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManifestation of acute edema in hereditary angioedema (HAE) is characterized by interindividual and intraindividual variability in symptom expression over time. Flexible therapy options are needed.
methodsWe describe and report on the outcomes of the highly individualized approach to HAE therapy practiced at our HAE center in Frankfurt (Germany).
resultsThe HAE center at the Frankfurt University Hospital currently treats 450 adults with HAE or AAE and 107 pediatric HAE patients with highly individualized therapeutic approaches. 73.9% of the adult patients treat HAE attacks by on-demand therapy with pasteurized pd C1-INH concentrate, 9.8% use additional prophylaxis with attenuated androgens, 1% of the total patient population in Frankfurt has been treated with Icatibant up to now. In addition adult and selected pediatric patients with a high frequency of severe attacks are instructed to apply individual replacement therapy (IRT) with pasteurized pd C1-INH concentrate. Improvement on Quality of Life items was shown for these patients compared to previous long-term danazol prophylaxis. Home treatment of HAE patients was developed in the Frankfurt HAE center in line with experiences in hemophilia therapy and has so far been implemented over a period of 28 years. At present 248 (55%) of the adult patients and 26 (24%) of the pediatric patients are practicing home treatment either as on demand or IRT treatment.
conclusionsIn conclusion, the individualized home therapies provided by our HAE center, aim to limit the disruption to normal daily activities that occurs for many HAE patients. Furthermore, we seek to optimize the economic burden of the disease while offering a maximum quality of life to our patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.